LCM
ABEO icon

Legato Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Legato Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59K Hold
13,180
– – 0.01% 710
2025
Q4 		$69.5K Buy
13,180
+2,290
+21% +$11.5K 0.01% 732
2025
Q3 		$57.5K Buy
+10,890
New +$69.1K 0.01% 545

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legato Capital Management's ABEO Position: Q1 2026 in Review

Legato Capital Management held its Abeona Therapeutics (ABEO) position steady in Q1 2026 at 13,180 shares worth $59K. The position accounts for 0.01% of the portfolio, ranked #710.

Legato Capital Management first reported a position in ABEO in Q3 2025 and has held it in 3 quarters since. The position peaked at $69.5K in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Legato Capital Management held 13,180 shares of Abeona Therapeutics worth $59K as of Q1 2026.
  • Legato Capital Management left its Abeona Therapeutics share count unchanged in Q1 2026.
  • Abeona Therapeutics made up 0.01% of Legato Capital Management's portfolio in Q1 2026, its #710 holding.
  • Legato Capital Management first reported a position in Abeona Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Legato Capital Management's Abeona Therapeutics position peaked at $69.5K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.